UNSPSC 51172150: Talnetant

This classification denotes an antispasmotic agent with the molecular formula C25H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CZ3T9T146K, chemically known as 4-quinolinecarboxamide, 3-hydroxy-2-phenyl-n-(1-phenylpropyl)-, (s)- but generally known as talnetant, which bears US NIH Compound Identifier 133090. European Medicines Agency schedules Talnetant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34015.

UNSPSC 51172150 Talnetant, a Commodity code, covers specimen collection, drug testing, and pharmaceutical procurement services that state and local governments buy to support criminal justice, public health, and employee health benefit programs. State and local buyers under this code include county corrections departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The scope of work spans offender drug testing operations—including specimen collection at multiple sites, immunoassay and confirmatory testing by LC/MS/MS or GC/MS, oral fluid and hair testing methodologies, and electronic result reporting—as well as direct pharmaceutical sourcing and generic multi-source drug procurement through authorized wholesaler networks. Testing and pharmaceutical services are procured on a per-test or per-unit basis with performance requirements tied to lab certification, manufacturing standards, and supply chain compliance.

Recent activity shows Collin County Community Supervision and Corrections Department issuing RFP 2026-327 for offender specimen collection and drug testing services, with proposals due July 23, 2026 at 2:00 p.m. and an estimated contract value of $600,000 over two years with three optional one-year renewals; the county seeks staffing at two sites in Plano and McKinney, IVR-based randomized testing notifications, screening and confirmation testing on approximately 25,031 annual tests, and SAMHSA or CAP lab certification. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with an April 3, 2026 response deadline to gather market intelligence on direct contracting models outside PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers for participating state and local government facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and administrative fee compliance. Recent solicitation activity concentrates in Texas and the Upper Midwest, with the Texas procurement focused on criminal justice specimen collection and the Minnesota and Texas HHS activity centered on pharmaceutical supply and direct-to-manufacturer sourcing.